Discover Arcutis Biotherapeutics' Q1 2025 earnings highlights: ZORYVE's growth, upcoming product launches, and a confident path to cash breakeven by 2026.

Q1 2025 net product revenue for ZORYVE ® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible ...